Talazoparib for metastatic breast cancer with BRCA body DNA changes
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic breast cancer with a harmful (deleterious) BRCA1 or BRCA2 mutation found in blood tumor DNA (not just a “germline” mutation).
- You do not have a BRCA1 or BRCA2 mutation in your germline (inherited) DNA.
- Your cancer subtype must be triple-negative ER/PR negative and HER2 negative, or hormone-receptor positive and HER2 negative—and it must have progressed after approved hormone or chemo treatment (as described).
- You must have at least 2 weeks since your last breast cancer treatment and be mostly recovered (generally side effects back to mild or baseline).
- You cannot have had a PARP inhibitor before, and you cannot start the study within 4 weeks of any other investigational drug.
- Blood counts, liver, and kidney tests must meet safety levels, and you must be able to use effective birth control (or not be able to become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
This Phase 2 trial tests whether combining ZEN003694 with talazoparib can slow or shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer. It is designed for people who have already been treated with a PARP inhibitor before, and it may help if that cancer comes back.
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.